addition, the time from referral to insertion increased significantly across these periods (p<0.01). In the later part of 2011 an increase in referrals and appropriate insertions was observed—without a concomitant rise in complications.

Conclusion Introduction of a “virtual” team for PEG assessment reduced the number of procedures required (freeing time for other endoscopic procedures), and post-insertion complications. There was a non-significant trend for improved 30-day mortality. A “minimal input” approach to PEG assessment based on a detailed referral form is therefore feasible, safe and associated with significantly reduced rates of post-procedure morbidity.

Competing interests None declared.

SAFETY AND SUBSEQUENT USE OF PROPHYLACTIC PERCUTANEOUS GASTROSTOMY PLACEMENT BY ENDOSCOPICALLY ASSISTED GASTROPEXY AND DIRECT PUNCTURE USING THE FRESENIUS® PEXACT KIT IN HEAD AND NECK CANCER PATIENTS

doi:10.1136/gutjnl-2012-302514b.85

S F Habib,* 1O Noorullah, 1N Stern, 2S N Rogers, 1S Ahmed. 1Department of Gastroenterology, University Hospital Aintree, Liverpool, UK, 2Maxillofacial Surgery, University Hospital Aintree, Liverpool, UK

Introduction Maintaining oral nutrition in Head and Neck cancer patients undergoing treatment can be challenging. Therefore, patients deemed at risk of malnutrition are referred for prophylactic gastrostomy. Due to risk of tumour implantation at gastrostomy site with conventional “pull though” technique, we changed our practice to direct puncture gastrostomy in 2004, using the Fresenius® PEXACT kit. We have previously reported series of 319 patients.

Methods All procedures performed between January 2010 and June 2011 were identified using the endoscopy reporting system. Information regarding readmissions, complications, mortality, dietetic assessment and use of gastrostomy tube was obtained from hospital patient records.

Results 91 gastrostomies were identified in 91 patients, 49 (54%) had advanced T3/T4 cancers, 10 (11%) with T2 disease. 69 (76%) were males. Mean age = 55 years (range 22–78). Insertion was successful in all patients. All patients had prophylactic antibiotics prior to the procedure. There were no immediate procedure related complications (two immediate complications, one requiring a laparotomy, in cohort reported earlier, n=319). There were no deaths within 7 days of procedure. Five patients died within 30 days (5.4%). Four were due to disease progression, one patient had a cardiac arrest in the community 23 days after the procedure. There was 1 (1.09%) unplanned admission 3 weeks after the procedure with bleeding from gastrostomy site requiring laparotomy. (14 unplanned admissions 30 days post procedure in earlier cohort, n=319). There were no readmissions within 7 days. No cases of tumour implantation reported to date. Late displacement of gastrostomy tube (>30 days after insertion) was common (6.5%, same as in earlier cohort). To date we have managed to get information regarding use of gastrostomy tube in 58 out of 91 patients. Available data so far has shown 46/58 (79.3%) patients used their gastrostomy tube for 2 weeks or more. 12/58 (20.6%) did not require use of gastrostomy tube. Laparotomy was necessary in one patient, with full recovery. The other the patient died following small bowel infarction. The availability of enteral route was particularly beneficial in 30 of our patients, to provide additional nutritional support for longer than anticipated, due to post operative difficulties including poor oral intake, anastomotic leak, and respiratory complications. In our series in only 5% (n=5) additional parenteral nutrition was necessary. This includes chyle leak—(n=3) and dislodged feeding tube (n=2).

Conclusion Feeding jejunostomy aids early establishment of enteral nutrition in patients undergoing upper GI cancer surgery. It is useful in providing continued nutritional support in patients who develop perioperative complications where oral route for nutrition is otherwise unavailable or inadequate, although jejunostomy tube placement and usage can also be a source of morbidity.

Competing interests None declared.

REFERENCE


HOW USEFUL IS FEEDING JEJUNOSTOMY IN UPPER GASTRO INTESTINAL CANCER SURGERY—A RETROSPECTIVE REVIEW

doi:10.1136/gutjnl-2012-302514b.86

V Daya Shetty,* K Akhtar. Department of Upper GI Surgery, Salford Royal Hospitals NHS Foundation Trust, Salford, UK

Introduction A retrospective review of outcome of 100 consecutive open feeding jejunostomies performed as part upper GI cancer surgery in our Centre in the last 5 years.

Methods 100 consecutive patients undergoing open insertion of Freka feeding jejunostomy as a part of Upper GI cancer surgery in the last 3 years are included. All feeding tubes were inserted approximately 30cms distal to the duodenoejunal flexure. The average procedure time for jejunostomy placement was 20 min. The feeding jejunostomy was flushed with water on the night of surgery and a standardised feeding regime initiated used from the first postoperative day. The standard regime was water at 20 ml/h on day 1 followed by feed (Jevity/Osmolyte) at 50 ml/h on day 2. The rate of feed was increased on daily increment of 10 ml/h/day to achieve target rate based on patient’s nutritional requirements. All patients were discharged with feeding jejunostomy in situ. It was removed at first follow-up clinic appointment 2 weeks after discharge if patient was nutritionally stable.

Results A total of 100 patients (male: female=66:34) who had feeding jejunostomy tubes inserted are included. The indications were cardio-oesophagectomy (77%); total gastrectomy (19%); inoperable tumour at laparotomy (5%) and in one patient prior to neoadjuvant chemotherapy. There were no intra operative procedure related complications. The median duration the feeding jejunostomy was in situ was 28 days (range 3–238 days). Postoperative feeding tube related complications were seen in 14% (n=14). These include tube failure (n=5); minimal leak (n=2) and skin puncture site cellulitis (n=7). Enteral feed related complications were seen in 15% (n=15). These complications were minor and they included diarrhea (n=9), abdominal cramps and bloating (n=4). Major complication was seen in only 6.8% (n=2) both due to feed (levity) forming a solid bezoar which caused small bowel obstruction. Laparotomy was necessary in one patient, with full recovery. The other the patient died following small bowel infarction. The availability of enteral route was particularly beneficial in 30 of our patients, to provide additional nutritional support for longer than anticipated, due to post operative difficulties including poor oral intake, anastomotic leak, and respiratory complications. In our series in only 5% (n=5) additional parenteral nutrition was necessary. This includes chyle leak—(n=3) and dislodged feeding tube (n=2).

Conclusion Feeding jejunostomy aids early establishment of enteral nutrition in patients undergoing upper GI cancer surgery. It is useful in providing continued nutritional support in patients who develop perioperative complications where oral route for nutrition is otherwise unavailable or inadequate, although jejunostomy tube placement and usage can also be a source of morbidity.

Competing interests None declared.

LAPAROSCOPIC INSERTION OF FREKA FEEDING JEJUNOSTOMY AS A PART OF LAPAROSCOPIC THORACOSCOPIC CARDIO-OESOPHAGECTOMY—A REVIEW OF OUR OUTCOME

doi:10.1136/gutjnl-2012-302514b.87

V Daya Shetty,* K Akhtar. Department of Upper GI Surgery, Salford Royal Hospitals NHS Foundation Trust, Salford, UK

Introduction A retrospective review of outcome of laparoscopic insertion of feeding jejunostomy as a part of laparoscopic thoracoscopic cardio-oesophagectomy.
Methods From October 2010 to January 2012 (15 months) 18 patients underwent laparoscopic thoracoscopic cardio-oesophagectomy. All 18 patients (12 male, 6 female) had laparoscopic insertion of Freka feeding jejunostomy are included in the study. The feeding jejunostomy was used for feeding from first post-operative day. The standard regime was water at 20 ml/h on day 1 followed by feed (jevity/osmolyte) at 50 ml/h on day 2. The rate of feed was increased at daily increments of 10 ml/h/day to achieve target rate to meet patient’s nutritional requirements. Patients were discharged with feeding jejunostomy in situ, removed at follow-up if nutritionally stable.

Results The average procedure time was 20 min. Median duration of feeding jejunostomy in situ was 3 weeks (range 8 days–6 weeks). Tube related complications, n=5 patients (tube failure-1, leak-2). Only one of these three patients needed additional parenteral nutrition. There were no procedure or feed related complications. The overall length of stay was not affected by this procedure. The availability of enteral route was useful in n=2 patients (chest infection-1, gastric stasis-1) for nutrition longer than the anticipated period.

Conclusion Laparoscopic insertion of feeding jejunostomy is safe, aids early establishment of enteral route for nutrition in patients undergoing cardio-oesophagectomy and useful in providing prolonged nutritional support in patients who develop complications were oral route is not possible.

Competing interests None declared.

Neoplasia (basic science)

**PMO-088 A LARGE PROPORTION OF COLORECTAL TUMOUR-INFILTRATING CD4+ T CELLS ARE SUPPRESSIVE IRRESPECTIVE OF FOXP3 EXPRESSION**

doi:10.1136/gutjnl-2012-302514b.88

M Scurr, A Gallimore, A Godkin,* Infection and Immunity, Cardiff University, Cardiff, UK

Introduction The presence of increased numbers of CD3+ T cells in colorectal cancer (CRC) correlates with improved prognosis. However, it is difficult to measure anti-tumour responses in tumour-infiltrating lymphocytes (TILs) suggesting these cells are suppressed. Although we have demonstrated CD4+Foxp3+ regulatory T cells (Tregs) within the tumour and its stroma, the numbers are often low. We sought to identify phenotypic and functional characteristics of CD4+Foxp3+ T cells to determine whether other regulatory populations exist within this environment.

Methods Tumour samples were obtained from CRC patients with different stages of malignancy. Fixed tumour samples were examined by immunofluorescence for CD3, CD8 and FoxP3. TILs from fresh tumour tissue were stained with a panel of 20 antibodies (including Helios, LAG-3, LAP) and examined by FACS.

Results Histology revealed tumours to be infiltrated by CD4+, CD8+ and Foxp3+ positive cells. Despite an increase in CD4+ and CD8+ T cells in advanced tumours, there was not always a concomitant increase in Foxp3+ cells. Flow cytometry revealed the majority of the Treg fraction was Helios+ (indicating thymically-derived) and expressed higher levels of CTLA-4 and CD59 than Tregs from colon and blood. However, 30% of “conventional” CD4+Foxp3+ T cells express markers associated with Tregs including LAP (latency-associated peptide), LAG-3 and CD25 and were highly suppressive in vitro.

Conclusion Tumour-infiltrating CD4+ T cells are heterogeneous. A high percentage of these cells appear to have a regulatory function and include both Foxp3+ as well as Foxp3- T cells. Overcoming the suppressive environment of CRC is a major challenge for boosting anti-tumour immunity.

Competing interests None declared.

REFERENCES


**PMO-090 GALECTIN-3 INDUCES SECRETION OF CYTOKINES FROM VASCULAR ENDOTHELIUM THAT ENHANCE CANCER CELL-ENDOTHELIUM ADHESION: A NOVEL MECHANISM FOR GALECTIN-3-MEDIATED METASTASIS PROMOTION**

doi:10.1136/gutjnl-2012-302514b.90

C Chen,* Q Zhao, J M Rhodes, L G Yu. Department of Gastroenterology, University of Liverpool, Liverpool, UK

Introduction Galectin-3 is a galactoside-binding protein whose concentration is increased up to 51-fold in the bloodstream of patients with cancer including colorectal cancer. We have recently...